Colorectal CancerPhase 1NCT00096330
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer
A Phase 1 study testing dietary intervention and folic acid in people with Colorectal Cancer, run by Roswell Park Cancer Institute at 1 site in United States.
Trial summary
RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the development of cancer. The use of folic acid may be effective in preventing colorectal cancer. Eating a diet rich in folic acid may prevent the development of colorectal cancer. Read more about this study
- Who is it for?
- Ages 40 to 72 yearsHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- dietary intervention and folic acid
- Type of treatment
- Pill or oral medicine
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2004to Mar 2008
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 72 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Healthy persons at increased risk for colorectal neoplasia due to 1 of the following reasons:
- Personal history of colorectal adenomatous polyps
- Family history of colorectal adenoma or adenocarcinoma
- No history of multiple family members with colorectal neoplasia that is suggestive of dominant hereditary neoplasia
PATIENT CHARACTERISTICS:
Age
- 40 to 72
Performance status
- Ambulatory
Life expectancy
- At least 6 months
Hematopoietic
- No excessive bleeding or coagulation disorder
Hepatic
- ALT or AST ≤ 2 times upper limit of normal
- No unexplained elevated alkaline phosphatase
Renal
- Creatinine ≤ 2.0 mg/dL
Cardiovascular
- Homocysteine concentration ≤ 17um/L
- No sustained blood pressure > 150/95 mm Hg for 3 consecutive readings
Other
- Vitamin B_12 ≥ 250 pg/mL
- Folate level ≤ 20 mg/dL
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 4 weeks after study participation
- No intestinal malabsorption or inflammatory bowel disease
- No prior malignancy except nonmelanoma skin cancer
- No calcium metabolism abnormalities or predisposing conditions, such as hyperparathyroidism
- No untreated hyperthyroidism
- No untreated insulin-requiring diabetes mellitus
- No daily alcohol intake > 2 ½ shot glasses of whiskey or three 8 ounce glasses of beer or wine
- No other serious illness that might limit life expectancy to < 6 months
PRIOR CONCURRENT THERAPY:
Biologic therapy
- None
Chemotherapy
- None
Endocrine therapy
- No concurrent hormone replacement therapy, including oral, transplanted, or injected contraceptives
- Concurrent thyroid hormone replacement is allowed as long as the patient is euthyroid for 3 months
Radiotherapy
- None
Surgery
- No prior gastrointestinal surgery, including gastrectomy or small or large bowel resections
- Prior appendectomy or surgery of the esophagus allowed
Other
- More than 3 months since regular ingestion of ≥ 650 mg per day of aspirin (≥ 2 tablets of 325 mg regular strength OR > 1 tablet of 500 mg extra strength aspirin)
- More than 3 months since regular daily ingestion of nonsteroidal anti-inflammatory drugs
- At least 1 month since vitamin, mineral, or herbal supplementation
- No other concurrent vitamin, mineral, or herbal supplementation
- No concurrent anticoagulants
- No concurrent sterol-binding resins (i.e., cholestyramine)
- No other concurrent investigational drugs or medications that might alter rectal mucosal proliferation, folate metabolism, or renal/hepatic impairment
- No concurrent weight control medications
- No concurrent supplemental folate preparations containing > 400 mcg of folic acid per day
- No concurrent lipid-lowering medications
- The following concurrent statin drugs are allowed provided patient has been taking a stable dose for ≥ 1 month:
- Atorvastatin 10 or 20 mg/day
- Fluvastatin 20 or 40 mg/day
- Lovastatin 10 or 20 mg/day
- Pravastatin 10 or 20 mg/day
- Simvastatin 5 or 10 mg/day
Trial locations and contacts
1 site in 1 country.
United States1 site
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
About this study
Official title: Phase I Clinical Study of Folate
RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the development of cancer. The use of folic acid may be effective in preventing colorectal cancer. Eating a diet rich in folic acid may prevent the development of colorectal cancer.
PURPOSE: This randomized phase I trial is studying how well a folate-depleted diet works compared to a folate-supplemented diet in preventing colorectal cancer in patients who are at high risk for developing colorectal cancer.
Read the detailed description
OBJECTIVES:
Primary
- Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints (e.g., genomic and gene-specific DNA methylation and DNA strand breaks) in rectal epithelial cells in patients at high risk for colorectal neoplasia.
- Analyze the effects of these dietary interventions on folate-related DNA endpoints (e.g., genomic and gene-specific DNA methylation, DNA strand breaks, and uracil incorporation into DNA) in blood mononuclear cells in these patients.
Secondary
- Analyze the effects of these dietary interventions on the patterns of differential gene expression in rectal epithelial cells and blood mononuclear cells in these patients.
OUTLINE: This is a randomized, single-blind study.
- Run-in period: Patients are placed on an average folate-containing diet for 56 days.
- Randomization: After completion of the run-in period, patients are randomized to 1 of 2 arms.
- Arm I (folate depleted diet): Patients are placed on a low-folate diet for 84 days. Patients receive oral folic acid supplementation once daily on days 57-84.
- Arm II (folate supplemented diet): Patients continue on an average folate-containing diet for an additional 56 days. Patients receive oral folic acid supplementation once daily on days 1-56.
Patients are followed at 4 weeks.
PROJECTED ACCRUAL: A total of 20 patients (10 per arm) will be accrued for this study within 2.5 years.
- Conditions
- Colorectal Cancer
- Being tested
- dietary intervention, folic acid
- Keywords
- colon cancer, rectal cancer
- Medical subject headings
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
dietary interventionDietary supplement
oral folic acid supplementation once daily on days 57-84
folic acidDietary supplement
oral folic acid supplementation once daily on days 1-56.
What is being measured
The primary outcome is the main question the study is designed to answer.
•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints
Measured: pre and post treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2004 (estimated)
- Study startSep 2004
- Primary completionFeb 2007
- Study completionMar 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Roswell Park Cancer InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Roswell Park Cancer Institute
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- James Marshall, PhD, Principal investigator, Roswell Park Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00096330
- Sponsor's protocol ID
- CDR0000393455
- Other IDs
- P30CA016056, RUH-PHO-0514-0404, RPCI-EPR-20703, AECM-0401022E, NEMCH-6060
- Status last verified
- Jan 2014
- First submitted
- 9 Nov 2004
- Last updated
- 13 Jan 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I Clinical Study of Folate
- ClinicalTrials.gov ID
- NCT00096330
- Acronym / sponsor ID
- CDR0000393455
- Conditions
- Colorectal Cancer
- Keywords
- colon cancer, rectal cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Roswell Park Cancer InstituteUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Sep 2004
- Primary completion
- Feb 2007 (actual)
- Study completion
- Mar 2008 (actual)
- First posted
- 9 Nov 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the development of cancer. The use of folic acid may be effective in preventing colorectal cancer. Eating a diet rich in folic acid may prevent the development of colorectal cancer.
PURPOSE: This randomized phase I trial is studying how well a folate-depleted diet works compared to a folate-supplemented diet in preventing colorectal cancer in patients who are at high risk for developing colorectal cancer.
Detailed description
OBJECTIVES:
Primary
- Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints (e.g., genomic and gene-specific DNA methylation and DNA strand breaks) in rectal epithelial cells in patients at high risk for colorectal neoplasia.
- Analyze the effects of these dietary interventions on folate-related DNA endpoints (e.g., genomic and gene-specific DNA methylation, DNA strand breaks, and uracil incorporation into DNA) in blood mononuclear cells in these patients.
Secondary
- Analyze the effects of these dietary interventions on the patterns of differential gene expression in rectal epithelial cells and blood mononuclear cells in these patients.
OUTLINE: This is a randomized, single-blind study.
- Run-in period: Patients are placed on an average folate-containing diet for 56 days.
- Randomization: After completion of the run-in period, patients are randomized to 1 of 2 arms.
- Arm I (folate depleted diet): Patients are placed on a low-folate diet for 84 days. Patients receive oral folic acid supplementation once daily on days 57-84.
- Arm II (folate supplemented diet): Patients continue on an average folate-containing diet for an additional 56 days. Patients receive oral folic acid supplementation once daily on days 1-56.
Patients are followed at 4 weeks.
PROJECTED ACCRUAL: A total of 20 patients (10 per arm) will be accrued for this study within 2.5 years.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 40 to 72 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| dietary interventionoral folic acid supplementation once daily on days 57-84 | Dietary supplement | – |
| folic acidoral folic acid supplementation once daily on days 1-56. | Dietary supplement | – |
Primary outcome
•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints
Time frame: pre and post treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2014.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James Marshall, PhD principal investigator
Roswell Park Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing dietary intervention and folic acid in people with Colorectal Cancer, run by Roswell Park Cancer Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints (time frame: pre and post treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2014.